Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.6K
2.6K
Metastasis02:30

Metastasis

5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Size Matters: Advanced Treatment of Acute Pulmonary Embolism Caused by a Large Snake-Like Thrombus.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026
Same author

Clinical, Metabolic, and Virological Insights into Hepatitis C Virus-Infected Patients through the Combinatorial Metabolic Dysfunction-associated Steatotic Liver Disease Framework: Evidence from an Italian Cohort.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

Safety of Invasive Procedures During Adult Extracorporeal Membrane Oxygenation: A Systematic Review.

Journal of clinical medicine·2026
Same author

Orthohantavirus Infection Mimicking Acute Viral Hepatitis: An Underrecognized Clinical Presentation.

Pathogens (Basel, Switzerland)·2026
Same author

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Cancer·2026

Related Experiment Video

Updated: Apr 23, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

903

NSCLC and HER2: between lights and shadows.

Giuseppina Rosaria Rita Ricciardi1, Alessandro Russo, Tindara Franchina

  • 1Medical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology, University of Messina, Messina, Italy.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|September 24, 2014
PubMed
Summary
This summary is machine-generated.

Targeted therapies are revolutionizing non-small-cell lung cancer (NSCLC) treatment. HER2 mutations are emerging as a key therapeutic target, driving the development of new anti-HER2 agents for personalized NSCLC care.

More Related Videos

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

8.2K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K

Related Experiment Videos

Last Updated: Apr 23, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

903
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

8.2K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small-cell lung cancer (NSCLC) treatment has shifted to a molecularly targeted approach.
  • Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations have led to successful targeted therapies.
  • Human epidermal growth factor-2 (HER2) pathway dysregulation is increasingly recognized in NSCLC.

Purpose of the Study:

  • To review the role of HER2 dysregulation in NSCLC.
  • To evaluate HER2 as a therapeutic target in NSCLC.
  • To discuss the strengths and weaknesses of current HER2-targeted studies in NSCLC.

Main Methods:

  • Literature review of studies on HER2 aberrations in NSCLC.
  • Analysis of clinical activity of anti-HER2 agents in HER2-mutated NSCLC.
  • Examination of HER2 amplification as a resistance mechanism to EGFR inhibitors.

Main Results:

  • HER2 aberrations are associated with varying sensitivity to EGFR inhibitors and may have prognostic value.
  • HER2 amplification is a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC.
  • HER2 mutations, particularly in-frame exon 20 insertions, represent a promising therapeutic target, with ongoing trials evaluating anti-HER2 agents.

Conclusions:

  • HER2 mutations are an emerging oncogenic driver in NSCLC, necessitating targeted therapeutic strategies.
  • Further research and rationally designed trials are crucial for the clinical implementation of HER2-targeted therapies in NSCLC.
  • Next-generation sequencing and multi-institutional platforms will advance personalized medicine for NSCLC patients with HER2 alterations.